Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Hutto

Optometrist High Point, NC Doctor of Optometry

NPI 1821191669 CMS profile 128648

6425 Old Plank Rd, Suite 105, High Point, NC 27265

Open in the dashboard

General payments

$20,093

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Hutto of High Point, NC is reported in the CMS Open Payments database as having received $20,093 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,376 67
2024 General $1,193 37
2023 General $1,245 30
2022 General $2,260 31
2021 General $697 33
2020 General $471 29
2019 General $852 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Hutto
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to William Hutto were reported at $13,376. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year William Hutto Optometrist median Middle half National median
2019 $852 $159 $67–$371 $163
2020 $471 $72 $29–$165 $114
2021 $697 $125 $46–$292 $132
2022 $2,260 $162 $66–$374 $149
2023 $1,245 $177 $72–$406 $160
2024 $1,193 $188 $77–$427 $164
2025 $13,376 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $7,592 77 payments
  2. Alcon Vision LLC $7,032 55 payments
  3. Johnson & Johnson Vision Care, Inc. $2,526 36 payments
  4. Bausch & Lomb Americas Inc. $1,282 36 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $464 18 payments
  6. Sun Pharmaceutical Industries Inc. $339 17 payments
  7. Tarsus Pharmaceuticals, Inc. $224 4 payments
  8. TissueTech, Inc. $126 2 payments
  9. Kala Pharmaceuticals, Inc. $112 2 payments
  10. Aerie Pharmaceuticals, Inc. $64 1 payment
  11. Other $331 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,360 6 payments
  2. Food and Beverage $7,003 257 payments
  3. Consulting Fee $1,730 1 payment
Products named General payments · program years 2019–2025
  1. CVI Contact Lens $6,000 1 payment
  2. Precision 1 $5,621 16 payments
  3. Precision7 $5,456 12 payments
  4. TOTAL30 $5,284 12 payments
  5. DAILIES TOTAL1 $5,110 4 payments
  6. Acuvue $2,431 31 payments
  7. INFUSE $1,085 28 payments
  8. MyDay Contact Lens $835 39 payments
  9. Multiple Brands Contact Lens $421 33 payments
  10. Cequa $339 17 payments
  11. Other $3,113 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

370

Median for Optometry: 120

Drug cost

$45,668

Median for Optometry: $8,864

Branded share of claims

33.5%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 31 $36,215
Fluorometholone Generic 25 $2,341
Travoprost Generic 11 $2,169
Latanoprost Generic 122 $1,484
Brimonidine Tartrate Generic 17 $1,111
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 33 $555
Dorzolamide Hcl Generic 14 $555
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 34 $366
Doxycycline Hyclate Generic 13 $353
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 26 $229

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$30,334

Medicare's payments for the services billed

Medicare patients

297

Average age 74

Services billed

3,518

190 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 28%
Chronic kidney disease 23%
Depression 21%
Ischemic heart disease 20%
Osteoporosis 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $186
$186 — —
MIEBO
  • Bausch & Lomb Americas Inc. $60
$60 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record